$109.86 $1.02 (0.0%)

03:38 PM EDT on 05/24/19

Spark Therapeutics, Inc. (NASDAQ:ONCE)

CAPS Rating: 5 out of 5

Current Price $109.86 Mkt Cap $4.2B
Open $109.00 P/E Ratio 0.00
Prev. Close $109.86 Div. (Yield) $0.00 (0.0%)
Daily Range $108.98 - $111.26 Volume 98,041
52-Wk Range $37.85 - $114.20 Avg. Daily Vol. 42

Caps

How do you think NASDAQ:ONCE will perform against the market?

Add Stock to CAPS Watchlist

All Players

52 Outperform
3 Underperform
 

All-Star Players

24 Outperform
1 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:ONCE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

SaintCroix (99.33)
Submitted December 23, 2017

The FDA has just approved their drug for a rare form of blindness. It's the first gene therapy for a genetic disease in human history. The price the company is talking about charging for this drug is $1 million dollars. And the reason they are… More

TSIF (99.97)
Submitted October 05, 2015

WARNING: BIOPHARMS on "news", (testing results, approvals) can overshoot, drop and climb much higher as shorts / speculators jockey with day traders to open and close positions... my thumbing is based on past patterns and the only rule I have about… More

NASDAQ:ONCE VS S&P 500 (SPY)

NASDAQ:ONCE Summary

Fools bullish on NASDAQ:ONCE are also bullish on:

Fools bearish on NASDAQ:ONCE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ONCE.

Recs

0
Member Avatar TMFBigFrog (95.08) Submitted: 6/2/2018 10:46:49 AM : Outperform Start Price: $80.78 NASDAQ:ONCE Score: +32.91

One recent approval and the potential for more. The adeno-associated virus vector it uses has shown success and looks promising for future therapies.

Recs

0
Member Avatar TMFTypeoh (94.06) Submitted: 5/31/2018 9:45:27 AM : Outperform Start Price: $78.52 NASDAQ:ONCE Score: +38.27

Through the FDA with one drug and more on the way

Recs

0
Member Avatar TMFEBCapital (91.22) Submitted: 12/7/2017 1:31:38 PM : Outperform Start Price: $71.02 NASDAQ:ONCE Score: +47.59

Gene therapy could revolutionize hemophilia A and B treatment for 130,000+ patients, removing the need for prophylactic infusions of missing clotting factor and eliminating or reducing the risk of life-threatening hemorrhages.

Leaderboard

Find the members with the highest scoring picks in ONCE.

Score Leader

paullng

paullng (< 20) Score: +334.06

The Score Leader is the player with the highest score across all their picks in ONCE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
paullng < 20 2/10/2016 Outperform 3Y $22.61 +385.89% +51.83% +334.06 0 Comment
portefeuille 98.17 2/10/2016 Outperform 5Y $23.30 +371.50% +50.75% +320.75 0 Comment
dollarsandcents1 < 20 4/6/2016 Outperform 5Y $32.29 +240.23% +38.54% +201.69 0 Comment
jeepdrew222 66.96 5/16/2016 Outperform 5Y $33.77 +225.32% +38.09% +187.23 0 Comment
NextGenStock < 20 2/8/2019 Outperform 5Y $46.47 +136.41% +5.31% +131.10 0 Comment
drugtrader 90.62 10/8/2018 Outperform 5Y $48.45 +126.75% -1.40% +128.15 0 Comment
IamaFOOL2 89.23 12/18/2017 Outperform 5Y $47.02 +133.65% +5.57% +128.08 0 Comment
jettyjett 59.92 1/4/2016 Outperform 5Y $41.33 +165.81% +41.52% +124.29 0 Comment
Dima 95.30 1/16/2018 Outperform 5Y $49.79 +120.66% +1.56% +119.10 0 Comment
stainsolution 25.18 12/20/2017 Outperform 5Y $50.19 +118.89% +5.50% +113.39 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.98 9/8/2016 Outperform 3W $59.90 +83.41% +29.52% +53.88 0 Comment
TrackJimCramer 85.98 9/28/2015 Underperform 3W $42.54 +40.81% +16.28% -24.52 9/8/2016 @ $59.90 0 Comment
TrackJimCramer 85.98 7/22/2015 Outperform 3W $67.15 -36.65% -11.07% -25.58 9/28/2015 @ $42.54 0 Comment

Advertisement